Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer

Annals of Oncology

Volumn 24, Issue 9, 2013, Pages 2316-2324

  Sinn, B V ^a   Von Minckwitz, G ^b   Denkert, C ^a   Eidtmann, H ^c   Darb Esfahani, S ^a   Tesch, H ^d   Kronenwett, R ^e   Hoffmann, G ^f   Belau, A ^g   Thommsen, C ^h   Holzhausen, H J ^h   Grasshoff, S T ⁱ   Baumann, K ^j   Mehta, K ^b   Dietel, M ^a   Loibl, S ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GERMAN BREAST GROUP   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d Bethanien Krankenhaus Frankfurt   (Germany)

^e Sividon Diagnostics GmbH   (Germany)

^f ST JOSEFS HOSPITAL   (Germany)

^g UNIVERSITY OF GREIFSWALD   (Germany)

^h MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

ⁱ Klinikum Quedlinburg   (Germany)

^j UNIVERSITY HOSPITAL MARBURG   (Germany)

more..

Author keywords

Breast cancer; Mucin 1; Neoadjuvant chemotherapy; pCR; Prognosis

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; HORMONE RECEPTOR; MESSENGER RNA; MUCIN 1; NAVELBINE; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR BIOPSY;

BREAST CANCER; MUCIN-1; NEOADJUVANT CHEMOTHERAPY; PCR; PROGNOSIS;

BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GENE EXPRESSION; HUMANS; MIDDLE AGED; MUCIN-1; NEOADJUVANT THERAPY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, MESSENGER; SURVIVAL; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84883364630     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt162     Document Type: Article

References (32)

1. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009; 9: 874-885.
2. Schroeder JA, Masri AA, Adriance MC et al. MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 2004; 23: 5739-5747.
3. Khodarev NN, Pitroda SP, Beckett MA et al. MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res 2009; 69: 2833-2837.
4. Finn OJ. Immunological weapons acquired early in life win battles with cancer late in life. J Immunol 2008; 181: 1589-1592.
5. Blixt O, Bueti D, Burford B et al. Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Res 2011; 13: R25.
6. Cheever MA, Allison JP, Ferris AS et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15: 5323-5337.
7. Butts C, Maksymiuk A, Goss G et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 2011; 137: 1337-1342.
8. von Minckwitz G, Blohmer JU, Raab G et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 2005; 16: 56-63.
9. von Minckwitz G, Kummel S, Vogel P et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008; 100: 552-562.
10. von Minckwitz G, Kummel S, Vogel P et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008; 100: 542-551.
11. Von Minckwitz G. Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients-results of the gepartrio trial. Cancer Res 2011; 71: 34s.
12. Remmele W, Hildebrand U, Hienz HA et al. Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch A Pathol Anat Histopathol 1986; 409: 127-147.
13. Bohmann K, Hennig G, Rogel U et al. RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods. Clin Chem 2009; 55: 1719-1727.
14. Budczies J, Klauschen F, Sinn BV et al. Cutofffinder: a comprehensive and straightforward Web application enabling rapid biomarker cutoffoptimization. PLoS One 2012; 7: e51862.
15. Li Y, Liu D, Chen D et al. Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene 2003; 22: 6107-6110.
16. Li Y, Yi H, Yao Y et al. The cytoplasmic domain of MUC1 induces hyperplasia in the mammary gland and correlates with nuclear accumulation of beta-catenin. PLoS One 2011; 6: e19102.
17. Mukhopadhyay P, Chakraborty S, Ponnusamy MP et al. Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta 2011; 1815: 224-240.
18. Kufe D, Inghirami G, Abe M et al. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984; 3: 223-232.
19. van der Vegt B, de Roos MA, Peterse JL et al. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. Histopathology 2007; 51: 322-335.
20. Rakha EA, Boyce RW, Abd El-Rehim D et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 2005; 18: 1295-1304.
21. Price MR, Rye PD, Petrakou E et al. Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996. Tumour Biol 1998; 19(Suppl 1): 1-20.
22. von Minckwitz G, Untch M, Blohmer JU et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796-1804.
23. Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334.
24. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8: 151-160.
25. Denkert C, Loibl S, Noske A et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-113.
26. Lakshminarayanan V, Thompson P, Wolfert MA et al. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc Natl Acad Sci USA 2012; 109: 261-266.
27. Quoix E, Ramlau R, Westeel V et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 2011; 12: 1125-1133.
28. Mohebtash M, Tsang KY, Madan RA et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res 2011; 17: 7164-7173.
29. Ibrahim NK, Yariz KO, Bondarenko I et al. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clin Cancer Res 2011; 17: 6822-6830.
30. Raina D, Ahmad R, Joshi MD et al. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res 2009; 69: 5133-5141.
31. Rubinstein DB, Karmely M, Ziv R et al. MUC1/X protein immunization enhances cDNA immunization in generating anti-MUC1 alpha/beta junction antibodies that target malignant cells. Cancer Res 2006; 66: 11247-11253.
32. Hu Y, Duan J, Zhan Q et al. Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro. PLoS One 2012; 7: e31970.